Monopar Therapeutics Inc. (MNPR) earnings

  • Healthcare
  • NASDAQ
  • Market cap$468M

Latest result

9 days ago

⁦+12.5%⁩EPS Beat

2026-11-12Q3 FY2026BMO
EPS
Reported / estimate-0.72 / -0.82

Stock reaction

⁦+1.32%⁩

⁦+1.68⁩ pts vs SPY

Session ⁦2026-11-12⁩

Next report

No scheduled report date right now.

Recent quarters

Latest 12 quarters

Revenue and stock reaction

Beat in 7 of 10 quarters with a measured stock reaction · beat then fell 3 · average move (last 8) ⁦±4.9%⁩

Reported / estimate

  • Q3 FY2026 · 2026-11-12+1.32%
    EPS-0.72 / -0.82+12.5%
    Revenue— / —
  • Q2 FY2026 · 2026-08-12+0.38%
    EPS-0.62 / -0.64+3.7%
    Revenue— / —
  • Q1 FY2026 · 2026-05-14-2.82%
    EPS-0.46 / -1.06+56.6%†
    Revenue— / —
  • Q4 FY2025 · 2026-03-27-1.50%
    EPS-0.61 / -0.51-19.1%
    Revenue— / —
  • Q3 FY2025 · 2025-11-13+5.36%
    EPS-0.48 / -0.46-4.3%
    Revenue— / —
  • Q2 FY2025 · 2025-08-12+14.55%
    EPS-0.35 / -0.47+25.5%
    Revenue— / —
  • Q1 FY2025 · 2025-05-13-3.65%
    EPS-0.38 / -0.65+41.5%
    Revenue— / —
  • Q1 FY2025 · 2025-03-31-9.72%
    EPS-2.23 / -0.36-519.4%‡
    Revenue— / —
  • Q3 FY2024 · 2024-11-08+7.31%
    EPS-0.37 / -0.46+19.6%
    Revenue— / —
  • Q2 FY2024 · 2024-08-09-19.64%
    EPS-0.50 / -0.45-11.1%
    Revenue— / —
  • Q1 FY2024 · 2024-05-09-5.07%
    EPS-0.50 / -0.85+41.2%
    Revenue— / —
  • Q4 FY2023 · 2024-03-28-7.59%
    EPS-0.60 / -0.85+29.4%
    Revenue— / —
  • †Unusually large: likely a one-off gain or charge, so not comparable with consensus
  • ‡A surprise beyond ±100% is usually a one-off item or a different basis, so it is left out of averages
  • Estimate recorded after the releaseNo estimate was saved before the results came out, so the surprise is measured against an estimate recorded after the release.

Reaction is the close of the reacting session versus the previous close. The gap to SPY is in percentage points.